Clinical Research Directory
Browse clinical research sites, groups, and studies.
ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.
Sponsor: Starship Child Health, Te Toka Tumai Auckland
Summary
The ACT4RHD trial is a multicentre, pragmatic, multi-arm, open-label adaptive platform trial addressing multiple therapeutic questions in patients with ARF and carditis. ACT4RHD aims to improve health outcomes for children and young people affected by ARF by finding treatments to reduce heart damage. The trial's Bayesian adaptive design enables multiple promising treatments to be tested at the same time. The trial will adapt by stopping treatments that are not effective sooner than traditional trials, adding new treatments as they become available, and answering research questions as soon as enough evidence has been collected. This flexibility allows researchers to identify the most effective treatments more quickly than traditional clinical trials.
Official title: ACT4RHD: Adaptive Collaborative Trial for Rheumatic Heart Disease
Key Details
Gender
All
Age Range
4 Years - 25 Years
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2026-12
Completion Date
2036-12
Last Updated
2026-10-07
Healthy Volunteers
No
Conditions
Interventions
Hydroxychloroquine (HCQ)
Hydroxychloroquine (HCQ)
No Hydroxychloroquine (HCQ)
No Hydroxychloroquine (HCQ)
Prednisone or Prednisolone
With or without initial pulsed Methylprednisolone / oral dexamethasone
No corticosteroid
No corticosteroid
Locations (3)
Royal Hospital
Darwin, Northern Territory, Australia
Starship Child Health, Te Toka Tumai, Auckland
Auckland, New Zealand
KidzFirst Hospital
Auckland, New Zealand